Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
MK-6194 by Merck for Vitiligo: Likelihood of Approval
MK-6194 is under clinical development by Merck and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs...
Data Insights
MK-6194 by Merck for Ulcerative Colitis: Likelihood of Approval
MK-6194 is under clinical development by Merck and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II...